Opto Circuits India Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Opto Circuits India Limited
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The Medicines Patent Pool has secured a licensing deal with MedinCell for a long-acting injectable ivermectin drug formulation which could be used to prevent ongoing spread of malaria.
- Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
In Vitro Diagnostics
- Other Names / Subsidiaries
- Advanced Micronic Devices Ltd.
- Cardiac Science Corporation
- Criticare Systems Inc.
- Devon Innovations Pvt Ltd.
- Eurocor Gmbh
- Maxcor Lifescience Inc.
- Mediaid Inc.
- N.S. Remedies Pvt. Ltd.
- Opto Cardiac Care Ltd.
- Opto Circuits (Malaysia) SDN BHD
- Opto Eurocor Healthcare Ltd.
- Opto Infrastructure Ltd.
- Ormed Medical Technology Ltd.
- Unetixs Vascular Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.